Emergent Nanotherapeutics in Diabetic Complications

1 Edición - 1 de noviembre de 2026
Última edición
Editores: Awanish Kumar, Gunjan Adwani
Idioma: Inglés

Emergent Nanotherapeutics in Diabetic Complications explores how cutting-edge nanotechnology is transforming the treatment of diabetes-related disorders beyond glycemic contro… Leer más

Descripción

Emergent Nanotherapeutics in Diabetic Complications explores how cutting-edge nanotechnology is transforming the treatment of diabetes-related disorders beyond glycemic control. This comprehensive volume examines targeted, multifunctional nanoplatforms designed to address the wide range of comorbidities linked to diabetes, including vascular complications, metabolic dysfunctions, and impaired wound healing. Structured in five parts, the book spans from current nanoformulation strategies to emerging innovations such as CRISPR-Cas9 delivery, AI-guided nanoparticles, and 3D/4D printed nanostructures. Bridging the gap between preclinical research and clinical application, it offers valuable guidance on stimuli-responsive systems, biocompatible materials, and regulatory pathways. Emergent Nanotherapeutics in Diabetic Complications is essential for medical professionals, biomedical engineers, and pharmaceutical scientists seeking scalable, next-generation solutions for managing diabetic complications through nanomedicine.

Puntos claves

Focuses on nanotherapeutics for diabetes-related complications, not just glucose control
Covers nano-drug delivery systems for improved wound healing and comorbidity management
Highlights next-generation technologies like CRISPR-Cas9, AI-driven nanoparticles, and 3D/4D nanostructures
Includes guidance on translational research, clinical development, and regulatory considerations

De interès para

Biomedical researchers, pharmaceutical scientists, and medical professionals working at the intersection of nanotechnology and diabetes treatment, particularly those focused on developing or applying advanced therapeutic strategies for diabetic complications

Índice

Part 1 Nanotherapeutics in Diabetic Comorbidities

1. Available nano-formulations in diabetes associated comorbidities and their mode of action for translational applications

2. Stimuli-responsive nanoplatforms for targeted drug release in diabetic complications: Clinical potential, scalability, and economic feasibility

3. Multifunctional nano-formulations: Integrating diagnosis, therapy, and real-time glucose monitoring for diabetic patients with current clinical status

Part 2 Nanotherapeutics for Microvascular Complications related to Diabetes

4. Nano-formulations for early-stage diabetic retinopathy: A visionary approach

5. Nano-formulations based renal protection: Combating diabetic nephropathy

6. Nano-formulations for diabetic neurpathy: Restoring nerve function

7. Engineering nanoparticles for improved bloodbrain barrier penetration in diabetic cognitive decline

Part 3 Nanotherapeutics for Macrovascular and Metabolic Complications related to Diabetes

8. Nano-formulation strategies for cardiovascular disease prevention in diabetes

9. Nanomedicine for hypertension in diabetes: Next-generation therapeutics for vascular protection

10. Nanotherapeutics for obesity-linked diabetes: A dual-action, effective approach

11. Nanotherapeutics for Dyslipidemia, NAFLD, and NASH: A multifaceted approach to metabolic liver disorders in diabetes

Part 4 Nanotherapeutics for Wound Healing and Tissue Regeneration in Diabetes

12. Nanotherapeutics for diabetic foot ulcers: Smart, clinically relevant wound healing and infection control for cost-effective care

13. Nano-formulation strategies for regenerative medicine in diabetes: Toward scalable and economical tissue restoration platforms

Part 5 Emerging Trends and Future Perspectives

14. Converging nanotechnology and CRISPR-Cas system revolutionize gene editing and diagnostics in diabetes

15. 3D and 4D printing of nanostructures: Clinically relevant and scalable technologies for revolutionizing diabetic wound healing

16. AI-driven design of nanotherapeutics for the treatment and management of personalized diabetes: Enhancing scalability, cost-effectiveness, and real-time glucose monitoring

Detalles del producto

Edición: 1
Última edición
Publicado: 1 de noviembre de 2026
Idioma: Inglés

Sobre los editores

Awanish Kumar

Dr. Awanish Kumar is an Associate Professor of the Department of Biotechnology at the National Institute of Technology, Raipur, Chhattisgarh, India. He has more than 13 years of research experience. He received his PhD in molecular parasitology from the CSIR-Central Drug Research Institute, Lucknow, India, and Jawaharlal Nehru University, Delhi, India, and completed his postdoctoral studies at McGill University, Montreal, Canada. His research interests are infection biology, drug targeting, and drug discovery.

Afiliaciones y experiencia

Associate Professor and Head, Department of Biotechnology, National Institute of Technology Raipur, India

Gunjan Adwani

Gunjan Adwani is a Ph.D. researcher in the Department of Biotechnology at the National Institute of Technology, Raipur, India. Her research focuses on nanomedicine, advanced drug delivery systems, and diabetes therapeutics, with a primary focus on optimizing insulin delivery strategies. She holds a Bachelor of Science and a Master of Science in Biotechnology from Pt. Ravishankar Shukla University, Raipur. Her current work involves the development of innovative nanocarrier platforms for targeted antidiabetic drug delivery and the formulation of therapeutic interventions to mitigate diabetic comorbidities.